drugset / Trial / NCT01878578

The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients

NCT01878578

Phase 1 Terminated 4 enrolled Bial - Portela C S.A.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is determine the interaction of eslicarbazepine acetate (ESL, BIA 2-093) on the steadystate pharmacokinetics of phenytoin in patients and to evaluate the tolerability and safety of ESL administered concomitantly with phenytoin in patients.

Timeline

Start
2002-11
Primary completion
2003-03
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 1200 mg
Comparator Phenytoin Unknown

Indications